Nafenopin
|
| Names
|
| IUPAC name
2-Methyl-2-[4-(1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]propanoic acid
|
| Other names
Nafenoic acid
|
| Identifiers
|
CAS Number
|
|
3D model (JSmol)
|
|
| ChEBI
|
|
| ChEMBL
|
|
| ChemSpider
|
|
| KEGG
|
|
|
|
|
| UNII
|
|
|
|
|
InChI=1S/C20H22O3/c1-20(2,19(21)22)23-16-12-10-15(11-13-16)18-9-5-7-14-6-3-4-8-17(14)18/h3-4,6,8,10-13,18H,5,7,9H2,1-2H3,(H,21,22) YKey: XJGBDJOMWKAZJS-UHFFFAOYSA-N YInChI=1S/C20H22O3/c1-20(2,19(21)22)23-16-12-10-15(11-13-16)18-9-5-7-14-6-3-4-8-17(14)18/h3-4,6,8,10-13,18H,5,7,9H2,1-2H3,(H,21,22) InChI=1S/C20H22O3/c1-20(2,19(21)22)23-16-12-10-15(11-13-16)18-9-5-7-14-6-3-4-8-17(14)18/h3-4,6,8,10-13,18H,5,7,9H2,1-2H3,(H,21,22) Key: XJGBDJOMWKAZJS-UHFFFAOYSA-N
|
O=C(O)C(Oc1ccc(cc1)C3c2ccccc2CCC3)(C)C
|
| Properties
|
Chemical formula
|
C20H22O3
|
| Molar mass
|
310.393 g·mol−1
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
|
Nafenopin is a hypolipidemic agent.[1]
References
Lipid-lowering agents (C10) |
|---|
| GI tract | | Cholesterol absorption inhibitors, NPC1L1 | |
|---|
| Bile acid sequestrants/resins (LDL) | |
|---|
|
|---|
| Liver | | Statins (HMG-CoA reductase, LDL) | |
|---|
| Niacin and derivatives (HDL and LDL) | |
|---|
| MTTP inhibitors (VLDL) |
- Dirlotapide
- Lomitapide
- Mitratapide
|
|---|
| ATP citrate lyase inhibitors (LDL) | |
|---|
| Thyromimetics (VLDL) | |
|---|
|
|---|
| Blood vessels | | PPAR agonists (LDL) | |
|---|
| CETP inhibitors (HDL) |
- Anacetrapib†
- Dalcetrapib§
- Evacetrapib§
- Obicetrapib†
- Torcetrapib§
|
|---|
| PCSK9 inhibitors (LDL) |
- Alirocumab
- Bococizumab
- Enlicitide†
- Evolocumab
- Inclisiran
- Lerodalcibep
|
|---|
| ANGPTL3 inhibitors (LDL/HDL) | |
|---|
|
|---|
| Combinations |
- Amlodipine/atorvastatin
- Bempedoic acid/ezetimibe
- Ezetimibe/atorvastatin
- Ezetimibe/rosuvastatin
- Ezetimibe/simvastatin
- Fenofibrate/pravastatin
- Fenofibrate/simvastatin
- Niacin/laropiprant
- Niacin/lovastatin
- Niacin/simvastatin
|
|---|
| Other |
- Alipogene tiparvovec
- Azacosterol
- Azalanstat
- Benfluorex‡
- Darapladib§
- Lapaquistat§
- Magnesium pyridoxal 5-phosphate glutamate
- Meglutol
- Mipomersen
- Olezarsen
- Omega−3-acid ethyl esters
- Plozasiran
- Policosanol
- Probucol
- Tiadenol
- Triparanol‡
- Volanesorsen
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|